{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:07:15Z","timestamp":1790226435918,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T08:56:39Z","timestamp":1584089799000},"page":"3201-3209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis"],"prefix":"10.1016","volume":"38","author":[{"given":"Sebastian","family":"Aston-Deaville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Feavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alistair Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Roseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Derrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.03.001_b0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0010","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero (R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.001_b0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","article-title":"Population structure and capsular switching of invasive neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine Era-United States, 2000\u20132005","volume":"201","author":"Harrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.001_b0020","doi-asserted-by":"crossref","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","article-title":"Meningococcal carriage and disease-population biology and evolution","volume":"27","author":"Caugant","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.001_b0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/infdis\/171.6.1481","article-title":"Antibodies to polysialic acid and its N-propyl derivative - finding properties and interaction with human embryonal brain glycopeptides","volume":"171","author":"Hayrinen","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.001_b0030","first-page":"U1015","article-title":"The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic","volume":"117","author":"Sexton","year":"2004","journal-title":"New Zealand Med J"},{"key":"10.1016\/j.vaccine.2020.03.001_b0035","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2020.03.001_b0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/0-387-25342-4_15","article-title":"Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis","volume":"568","author":"Kelly","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0050","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.03.001_b0055","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.001_b0060","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.03.001_b0065","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature07769","article-title":"Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates","volume":"458","author":"Schneider","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.03.001_b0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.03.001_b0075","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults","volume":"8","author":"Sheldon","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.03.001_b0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1107\/S1744309111006154","article-title":"Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086)","volume":"67","author":"Cendron","year":"2011","journal-title":"Acta Crystall Sect F-Struct Biol Crystall Commun"},{"key":"10.1016\/j.vaccine.2020.03.001_b0085","doi-asserted-by":"crossref","first-page":"41767","DOI":"10.1074\/jbc.M111.289314","article-title":"Structure of the C-terminal Domain of Neisseria Heparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine against Neisseria meningitidis","volume":"286","author":"Esposito","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.03.001_b0090","doi-asserted-by":"crossref","first-page":"17128","DOI":"10.1073\/pnas.1419686111","article-title":"Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody","volume":"111","author":"Malito","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.03.001_b0095","doi-asserted-by":"crossref","first-page":"e01914","DOI":"10.1128\/mBio.01914-18","article-title":"NadA3 structures reveal undecad coiled coils and LOX1 binding regions competed by meningococcus B vaccine-elicited human antibodies","volume":"9","author":"Liguori","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2020.03.001_b0100","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.001_b0105","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.8248784","article-title":"The influence of antigen organization on B-cell responsiveness","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.03.001_b0110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/jcm.30.6.1617-1619.1992","article-title":"Stability of the recombinant hepatitis-B core antigen","volume":"30","author":"Nath","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0115","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1126\/science.3491425","article-title":"The nucleocapsid of hepatitis-B virus is both a T-cell independent and a T-cell-dependent antigen","volume":"234","author":"Milich","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.03.001_b0120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","article-title":"Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines","volume":"26","author":"Wheeler","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.001_b0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijid.2006.09.010","article-title":"Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens","volume":"11","author":"Betancourt","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.001_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0006-8","article-title":"Escherichia coli-derived virus-like particles in vaccine development","volume":"2","author":"Huang","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.03.001_b0135","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.1073\/pnas.95.16.9477","article-title":"T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles","volume":"95","author":"Fehr","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.03.001_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001556","article-title":"Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of plasmodium falciparum circumsporozoite protein","volume":"3","author":"Gregson","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.03.001_b0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jmb.2012.06.032","article-title":"Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies","volume":"423","author":"Roseman","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The crystal structure of the human hepatitis B virus capsid","volume":"3","author":"Wynne","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.vaccine.2020.03.001_b0155","doi-asserted-by":"crossref","first-page":"15821","DOI":"10.1073\/pnas.0504874102","article-title":"A structural model for maturation of the hepatitis B virus core","volume":"102","author":"Roseman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.03.001_b0160","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1128\/jvi.63.11.4645-4652.1989","article-title":"A recombinant hepatitis-B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic-acids","volume":"63","author":"Gallina","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0165","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s12033-015-9895-9","article-title":"The hepatitis B virus core variants that expose foreign C-terminal insertions on the outer surface of virus-like particles","volume":"57","author":"Dishlers","year":"2015","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075938","article-title":"A VLP library of C-terminally truncated hepatitis B core proteins: correlation of RNA encapsidation with a Th1\/Th2 switch in the immune responses of mice","volume":"8","author":"Sominskaya","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.03.001_b0175","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1073\/pnas.89.21.10046","article-title":"Hepatitis B virus capsid particles are assembled from core-protein dimer precursors","volume":"89","author":"Zhou","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.03.001_b0180","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/09687680802541169","article-title":"Characterization of a CorA Mg2+transport channel from Methanococcus jannaschii using a Thermofluor-based stability assay","volume":"25","author":"Kean","year":"2008","journal-title":"Mol Membr Biol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0185","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1107\/S2059798317007859","article-title":"Recent developments in the CCP-EM software suite","volume":"73","author":"Burnley","year":"2017","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.vaccine.2020.03.001_b0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1107\/S2059798318006551","article-title":"Real-space refinement in PHENIX for cryo-EM and crystallography","volume":"74","author":"Afonine","year":"2018","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.vaccine.2020.03.001_b0195","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1073\/pnas.1222845110","article-title":"Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen","volume":"110","author":"Malito","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.03.001_b0200","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.03.001_b0205","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.vaccine.2016.01.044","article-title":"A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults","volume":"34","author":"Ostergaard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.001_b0210","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.03.001_b0215","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/IAI.72.7.4217-4223.2004","article-title":"NadA diversity and carriage in Neisseria meningitidis","volume":"72","author":"Comanducci","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.03.001_b0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpb.2015.07.002","article-title":"His-tagged norovirus-like particles: a versatile platform for cellular delivery and surface display","volume":"96","author":"Koho","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2020.03.001_b0225","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/bit.25311","article-title":"The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine","volume":"111","author":"Tyler","year":"2014","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2020.03.001_b0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12033-014-9743-3","article-title":"Mosaic RNA phage VLPs carrying domain III of the West Nile Virus E protein","volume":"56","author":"Cielens","year":"2014","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.001_b0235","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2020.03.001_b0240","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/toxsci\/kfw121","article-title":"Subvisible aggregates of immunogenic proteins promote a Th1-type response","volume":"153","author":"Ratanji","year":"2016","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.vaccine.2020.03.001_b0245","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a rugged nanoscaffold to enhance plug-and-display vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2020.03.001_b0250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1371\/journal.pone.0120751","article-title":"Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins","volume":"10","author":"Peyret","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.03.001_b0255","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0161-5890(78)90123-2","article-title":"Effect of immune complex composition on complement activation and complement-dependent complex release","volume":"15","author":"Rajnavolgyi","year":"1978","journal-title":"Immunochemistry"},{"key":"10.1016\/j.vaccine.2020.03.001_b0260","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1- and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"key":"10.1016\/j.vaccine.2020.03.001_b0265","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/bioinformatics\/18.1.211","article-title":"DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra","volume":"18","author":"Lobley","year":"2002","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2020.03.001_b0270","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:28Z","timestamp":1759401688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":54,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X20303273"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}